Biofrontera Inc. SEC filings BFRI
Biofrontera Inc. has 365 filings in SEC EDGAR's recent list, going back to May 7, 2021. Its latest annual report, Form 10-K, was filed on Mar 19, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 14, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 25-NSE | Delisting notice | Oct 30, 2026 | — |
| EFFECT | Filing | Dec 19, 2025 | — |
| CORRESP | Letter to the SEC | Dec 17, 2025 | — |
| EFFECT | Filing | Aug 19, 2025 | — |
| CORRESP | Letter to the SEC | Aug 15, 2025 | — |
| D | Filing | Jul 11, 2025 | — |
| DEFR14A | Filing | Jun 3, 2025 | — |
| EFFECT | Filing | Jan 28, 2025 | — |
| CORRESP | Letter to the SEC | Jan 24, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 22, 2025 | — |
| D | Filing | Dec 5, 2024 | — |
| EFFECT | Filing | May 9, 2024 | — |
| CORRESP | Letter to the SEC | May 8, 2024 | — |
| UPLOAD | Letter from the SEC | May 8, 2024 | — |
| DEFR14A | Filing | Apr 30, 2024 | — |
| EFFECT | Filing | Apr 22, 2024 | — |
| CORRESP | Letter to the SEC | Apr 22, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 18, 2024 | — |
| D | Filing | Mar 5, 2024 | — |
| RW | Filing | Feb 20, 2024 | — |
| EFFECT | Filing | Oct 30, 2023 | — |
| CORRESP | Letter to the SEC | Oct 27, 2023 | — |
| CORRESP | Letter to the SEC | Oct 13, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 11, 2023 | — |
| 8-A12B/A | Filing | Apr 28, 2023 | — |
| DEFR14A | Filing | Nov 14, 2022 | — |
| EFFECT | Filing | Nov 7, 2022 | — |
| D | Filing | Nov 4, 2022 | — |
| CORRESP | Letter to the SEC | Nov 3, 2022 | — |
| 8-A12B | Filing | Oct 14, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 30, 2022 | — |
| DRS | Filing | Aug 29, 2022 | — |
| DRSLTR | Filing | Aug 26, 2022 | — |
| D | Filing | Aug 11, 2022 | — |
| EFFECT | Filing | Jun 13, 2022 | — |
| EFFECT | Filing | Jun 9, 2022 | — |
| CORRESP | Letter to the SEC | Jun 7, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 1, 2022 | — |
| DRSLTR | Filing | May 27, 2022 | — |
| DRS | Filing | May 27, 2022 | — |
| D | Filing | May 23, 2022 | — |
| POS EX | Filing | Apr 11, 2022 | — |
| POS EX | Filing | Apr 11, 2022 | — |
| NT 10-K | Filing | Apr 1, 2022 | Dec 31, 2021 |
| EFFECT | Filing | Dec 23, 2021 | — |
| CORRESP | Letter to the SEC | Dec 21, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2021 | — |
| DRSLTR | Filing | Dec 14, 2021 | — |
| DRS | Filing | Dec 14, 2021 | — |
| D | Filing | Dec 10, 2021 | — |
| EFFECT | Filing | Oct 28, 2021 | — |
| SEC STAFF LETTER | Filing | Oct 28, 2021 | — |
| CERT | Filing | Oct 28, 2021 | — |
| 8-A12B/A | Filing | Oct 27, 2021 | — |
| CORRESP | Letter to the SEC | Oct 27, 2021 | — |
| CORRESP | Letter to the SEC | Oct 27, 2021 | — |
| CORRESP | Letter to the SEC | Oct 20, 2021 | — |
| CORRESP | Letter to the SEC | Oct 20, 2021 | — |
| 8-A12B | Filing | Oct 20, 2021 | — |
| CORRESP | Letter to the SEC | Oct 18, 2021 | — |
| CORRESP | Letter to the SEC | Oct 18, 2021 | — |
| CORRESP | Letter to the SEC | Oct 14, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 14, 2021 | — |
| CORRESP | Letter to the SEC | Oct 13, 2021 | — |
| CORRESP | Letter to the SEC | Oct 13, 2021 | — |
| CORRESP | Letter to the SEC | Oct 13, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 12, 2021 | — |
| CORRESP | Letter to the SEC | Oct 8, 2021 | — |
| CORRESP | Letter to the SEC | Oct 8, 2021 | — |
| CORRESP | Letter to the SEC | Oct 8, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 7, 2021 | — |
| SEC STAFF LETTER | Filing | Sep 17, 2021 | — |
| CORRESP | Letter to the SEC | Sep 15, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 9, 2021 | — |
| CORRESP | Letter to the SEC | Aug 30, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 20, 2021 | — |
| CORRESP | Letter to the SEC | Aug 11, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 2, 2021 | — |
| CORRESP | Letter to the SEC | Jul 23, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 19, 2021 | — |
| CORRESP | Letter to the SEC | Jul 6, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 1, 2021 | — |
| DRS/A | Filing | Jun 22, 2021 | — |
| DRSLTR | Filing | Jun 21, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 10, 2021 | — |
| DRS/A | Filing | May 11, 2021 | — |
| DRS | Filing | May 7, 2021 | — |
Showing 87 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BFRI (Nasdaq), BFRIW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Woburn, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1858685
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.